Comparison & De-risking
of Downstream Processing Techniques
"I have been very impressed with the work done by IBioIC . They have undertaken the work promptly and professionally. Communication has been excellent between us and I have been kept informed of progress, results or any issues in a timely manner. I am happy that I have been able to obtain further funding to extend the project"
Dr April Roberts, Senior Research Project Manager
Public Health England
Public Health England (PHE) and MicroPharm Limited, a subsidiary of Flynn Pharma, have been collaborating since 2008 to explore a non-antibiotic treatment for Clostridium difficile infections which are common in the very young and elderly. Through this partnership, immunotherapeutic polyclonal antibodies were successfully developed which target and eliminate the toxins which produce the undesirable symptoms of the infection.
IBioIC collaborated with PHE and MicroPharm Limited to assess the replicability of their developed antibody production method and also to provide a comparable investigation into the effects of different harvesting and downstream processing techniques on cell productivity.
Our Technical Team successfully demonstrated replicability of the partners' existing fermentation at 30 L. Cell harvesting by standard batch centrifugation was then compared to continuous disk-stack centrifugation, a method which more closely represents the processing cells would undergo at industrial-scale. Cells were processed efficiently using both methods. However, the antibody yield from cells isolated by disk-stack processing was found to be almost double that achieved with cells from the standard batch method.
This study provided promising results to support and de-risk the use of continuous centrifugation in future process scale-up, as a more effective method of processing cells for higher yields of therapeutic polyclonal antibodies for treatment of Clostridium difficile infection.